Clinical trials: Non-HIV
Chronic Hepatitis C
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients
To compare the sustained virological response (SVR = ribonucleic acid (RNA) - hepatitis C virus (HCV) undetectable at week 24 before end the treatment) in chronic hepatitis C patients genotype 1-4 co-infected with HIV-HCV…
- Trial name
- PERICO (NCT00526448)
- Testing
- ribavirin, Peginterferon alfa-2a, epoetin beta
- Where
- 40 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Hospital Carlos III, Madrid
Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected.
- Conditions
- Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
- Trial name
- NCT04742387
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Pneumonia, Meningitis
Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection
Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces.
- Conditions
- Pneumonia, Meningitis, Invasive Pneumococcal Disease, HIV
- Trial name
- NCT00371878
- Testing
- 7-valent pneumococcal conjugate vaccine (Prevnar)
- Where
- Malawi
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Liverpool University Hospital
HIV-1 Infection
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
The purpose of this study is to determine the pharmacokinetic profile of TMC125 400mg with tenofovir DF/emtricitabine FDC (fixed dose combination) 300/200mg all dosed once daily with and without darunavir/ritonavir 800/100 mg…
- Trial name
- NCT00534352
- Testing
- TMC125; darunavir; ritonavir
- Volunteers
- 23 people
- Sponsor
- Tibotec, Inc